Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025

Reuters

08/11

Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025

Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), focusing on its impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811966575) on August 11, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2558106650"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558106650\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558106650?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558106650","market":"fut","top_or_hot":-1,"title":"Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), focusing on its impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811966575) on August 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-11 20:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), focusing on its impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811966575) on August 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL10cbBx:1","article_id":"2558106650","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558106650","pubTimestamp":1754913776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis  programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA , focusing on its impact on transthyretin amyloidosis with cardiomyopathy , including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","ALNY":"阿尔尼拉姆制药公司","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4139":"生物科技"},"translate_title":"Alnylam Pharmaceuticals在2025年ESC大会上公布了高血压和ATTR项目试验的有希望的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":0.9},"content_text":"Alnylam Pharmaceuticals Unveils Promising New Data from Hypertension and ATTR Program Trials at ESC Congress 2025\n    \n\n        Alnylam Pharmaceuticals Inc. has announced the presentation of new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the European Society of Cardiology Congress 2025, scheduled to take place in Madrid, Spain, from August 29 to September 1, 2025. The company will present findings from Cohort A of the KARDIA-3 Phase 2 study, which evaluates the investigational RNAi therapeutic, zilebesiran, for patients with uncontrolled hypertension and high cardiovascular risk. These results will be part of a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, Alnylam will share data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), focusing on its impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including 12-month follow-up results and effects on days lost to death and/or hospitalization. The presentations aim to highlight the potential of RNAi therapeutics in transforming cardiovascular disease treatment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250811966575) on August 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}